SHPH: Shuttle Pharmaceuticals Price/Earnings to Growth Ratio

Symbol and logo of brand Shuttle Pharmaceuticals (SHPH)

The growth of Shuttle Pharmaceuticals (SHPH) is driven by the progress of Ropidoxuridine and merger and acquisition potential. The valuation-to-earnings growth ratio visualizes this momentum, where 0.00 reflects the latest metric value. Demand for oncology care remains independent of economic cycles, while patent protection for radiosensitizers creates a robust barrier, determining the future margins of the company's R&D projects.

SHPH: Shuttle Pharmaceuticals Holdings PEG Multiple 04/28/2023 - 11/10/2026

Metric breakdowns and analytics for Shuttle Pharmaceuticals (SHPH)

- share price and consensus valuation forecast:
Price Performance Chart Shuttle Pharmaceuticals Holdings, Inc.|SHPH - Analyst Consensus Forecast
- market capitalization information:
Market Value Shuttle Pharma|SHPH - Total Company Value
- issuer book value statistics:
Accounting Value of a Share Shuttle Pharmaceuticals|SHPH - Book Capitalization|Market Capitalization to Book Value Ratio shuttlepharma.com|SHPH - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Shuttle Pharmaceuticals|SHPH - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio shuttlepharma.com|SHPH - Company Debts|Debts to Net Assets Shuttle Pharma|SHPH - Company Long-Term Debts|Company Short-Term Loans and Borrowings Shuttle Pharmaceuticals|Quick Ratio shuttlepharma.com
- earnings and valuation multiples information:
SHPH - Net Income|Future Net Profit Shuttle Pharmaceuticals|SHPH - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Shuttle Pharmaceuticals Inc|SHPH - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shuttle Pharma|SHPH - Operating profit EBITDA|Net earnings per one share for the last twelve months Shuttle Pharmaceuticals|SHPH - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months shuttlepharma.com|SHPH - Earnings per share growth in current year|Net earnings per share change forecast for next year Shuttle Pharmaceuticals
Fundamental company analysis:SHPH, Shuttle Pharmaceuticals Holdings, Inc.
Core merchandise of Shuttle Pharmaceuticals Holdings, Inc.

Professional selection of undervalued assets is based on identifying the gap between market value and earnings dynamics. By correlating the P/E multiple with revenue growth rates, the PEG filter for undervalued "rockets" identifies securities with expansion potential, which for Shuttle Pharmaceuticals (SHPH) is confirmed by the uniqueness of its oncology patents and the absence of pricing pressure from competitors.

Competing companies

CNSP (CNS Pharmaceuticals Inc) - Growth-Adjusted Payback Ratio